San Francisco, CA and Munich, Germany – March 18, 2026 – Biocare Medical, a provider of immunohistochemistry (IHC) and in situ hybridization (ISH) reagents and staining platforms, today announced a strategic co-exclusive distribution partnership with PreciPoint GmbH, a developer and manufacturer of compact digital pathology solutions for modern pathology laboratories. Under the agreement, Biocare will […]

San Francisco, CA and Bridgewater, NJ – October 30, 2025 – Biocare Medical, a global leader in immunohistochemistry instrumentation, antibodies and reagents, and Hamamatsu Corporation, a worldwide innovator in imaging technologies, today announced a strategic collaboration to accelerate innovation in the rapidly expanding field of spatial biology. Under the agreement, Biocare will co-exclusively offer Hamamatsu’s […]

[San Francisco, California], [March 12, 2025] – Vitro, a global developer, manufacturer and marketer of integral diagnostics solutions and data integration in Cancer Diagnostics, today announced that it has appointed Biocare Medical, a global leader in advanced staining solutions and reagents, as the exclusive distributor for its new NeoPATH Pro instrument in the United States. […]

In the rapidly changing laboratory landscape, there are many valuable techniques that identify and produce different amounts of diagnostic information. In this white paper, discover the power of FISH and NGS. Learn how these techniques can be used to identify genetic abnormalities, perform genome-wide analysis, and detect disease-related variants. Understand the advantages and disadvantages of […]

[San Francisco, California, September 4, 2024] – Biocare Medical, a global leader in immunohistochemistry (IHC) instrumentation and reagents, together with Ensigna Biosystems, a renowned provider of advanced histopathology services, are excited to announce a new strategic partnership. This collaboration seeks to enable and broaden the scope of innovative spatial biology applications that are essential for […]

Fluorescence in situ hybridization (FISH) probes have become a cornerstone of cytogenetic analysis in hematological malignancies. These targeted probes allow for the detection of specific chromosomal abnormalities associated with various leukemias and myelodysplastic syndromes (MDS). This white paper will explore the importance of FISH probes for Chronic Lymphocytic Leukemia (CLL) and Myelodysplastic Syndromes (MDS)

Nucleic acid probes are invaluable tools in molecular biology, enabling clinical laboratories and researchers to detect specific DNA or RNA sequences within a sample. In this white paper, we explore the key differences between three prominent probe types: DNA probes, RNA probes, and cDNA probes. We delve into their what they are, how they are […]

The use of a curated selection of antibodies to target protein characteristics of distinct cell lineages has been in practice in clinical laboratories for many years. The ability for pathologists to identify cells of unknown origin via the use of Immunohistochemistry (IHC) is extremely important to aid in the diagnosis, treatment, and prognosis for their […]

Buffalo, New York – April 1, 2024 – Empire Genomics Corp has been awarded a national group purchasing agreement for Molecular Analyzers, Reagents with Premier, Inc. Effective 02/01/2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for FISH (Fluorescent in situ Hybridization) Probes. […]